Madan Babu Mohan
Member, Endowed Chair in Biomedical Data Science
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (6)
Highly pathogenic avian influenza A(H5N1) hemagglutinin (HA) clade 2.3.4.4b viruses are now circulating in wild birds and agricultural species (poultry and dairy cows), resulting in multiple human infections. Both preclinical and clinical data for treating A(H5N1) with US Food and Drug Administration–approved anti-influenza drugs are limited. Here, we examined the protection conferred by one, two, or three doses of the newest approved anti-influenza drug, baloxavir, in ferrets lethally challenged with either an avian- or bovine-origin A(H5N1) virus. All dosing regimens improved survival and clinical outcomes with protection ranging from 50 to 100%. Compared with vehicle-only treatment, baloxavir regimens decreased virus shedding, lung pathology, and viremia and eliminated viral spread to the brain. Multidose therapy yielded the best outcomes overall. Single-dose baloxavir prophylaxis with an avian virus challenge resulted in the low-frequency presence of polymerase acidic (PA) protein containing the E23K substitution, whereas all treatment regimens after a bovine-origin virus challenge induced at least one instance of PA containing the I38T substitution. Both PA-E23K and PA-I38T were predicted to decrease potential baloxavir–PA protein interactions, and they phenotypically reduced susceptibility of the virus to baloxavir by 3.8-fold [50% effective concentration (EC 50 ) = 15.13 nanomolar, PA-E23K] and 77.3-fold (EC 50 = 307.40 nanomolar, PA-I38T) in polymerase assays. Baloxavir is a single-dose drug for treating seasonal influenza. We show that multidose regimens of baloxavir may be most efficacious against highly pathogenic avian influenza A(H5N1) in a preclinical ferret model, with effective control of both severe disease and neurological involvement.
Year:
2026
Somatic mitochondrial DNA (mtDNA) mutations are frequently observed in tumors, yet their role in pediatric cancers remains poorly understood. The heteroplasmic nature of mtDNA—where mutant and wild-type mtDNA coexist—complicates efforts to define its contribution to disease progression. In this study, bulk whole-genome sequencing of 637 matched tumor-normal samples from the Pediatric Cancer Genome Project revealed an enrichment of functionally impactful mtDNA variants in specific pediatric leukemia subtypes. Collectively, the results from single-cell sequencing of five diagnostic leukemia samples demonstrated that somatic mtDNA mutations can arise early in leukemogenesis and undergo positive selection during disease progression, achieving intermediate heteroplasmy—a “sweet spot” that balances mitochondrial dysfunction with cellular fitness. Network-based systems biology analyses link specific heteroplasmic mtDNA mutations to metabolic reprogramming and therapy resistance. We reveal somatic mtDNA mutations as a potential source of functional heterogeneity and cellular diversity among leukemic cells, influencing their fitness and shaping disease progression.
Year:
2025
Biomolecular condensates mediate dynamic compartmentalization of cellular processes. The multivalent interactions that underlie biomolecular condensation are often promoted by intrinsically disordered regions (IDRs) within proteins. Although the role of IDRs in biomolecular condensates is well appreciated, predicting whether an IDR forms condensates in cells remains challenging. Here, we developed a machine learning model to accurately predict the condensation behavior of IDRs, analyzing 215 IDRs from fusion oncoproteins in human embryonic kidney (HEK) 293T cells. We identified distinct sequence-derived physicochemical features associated with condensation. Leveraging these data, our model predicts that ~12% of the ~13,000 IDRs in the human proteome are likely to form cellular condensates, establishing a robust framework for proteome-wide analysis of IDR-mediated biomolecular condensation. Notably, proteins with condensate-forming IDRs are significantly enriched in RNA processing and splicing functions and are predominantly localized to membraneless organelles, highlighting a central role of IDR-mediated biomolecular condensation in cellular organization and RNA biology.
Year:
2025
Post-translational modifications (PTMs) alter the proteome in response to intra- and extracellular signals, providing fundamental information processing in development, homeostasis and disease 1–5 . Here, we used proteome-wide structure predictions to investigate the structural context of protein modification sites and found nearly a fifth to be buried within proteins 6 . These cryptic sites within folded domains showed evolutionary conservation across species, as well as significantly less variability within the human population. We also found significantly more modification sites to be affected by recurrent cancer mutations and disease variants, with some variants appearing to mimic the modified or unmodified state, supporting their functionality and disease relevance. To understand how these buried sites become modified, we studied 23 phosphorylation sites across seven proteins using all-atom molecular dynamics simulations. The simulations revealed a range of mechanisms spanning broad timescales, ranging from picosecond fluctuations to seconds for proline isomerisation-gated phosphorylation sites. Notably, some sites remained fully buried in the native structure. Some conformational states with exposed cryptic sites resembled structures of co-translational protein folding intermediates formed on the ribosome 7 , indicating an interplay between protein biogenesis, folding, modifications, and signalling. We propose more broadly that protein conformational fluctuations may serve as structure-specific regulatory mechanisms by kinetically burying or exposing the unmodified, and in some cases even modified, sidechains, thereby expanding the functional versatility of proteins and enabling signal transduction across diverse timescales.
Year:
2025
Synchronizing protein structure predictions with sequence databases is crucial for their accuracy. We developed AlphaSync ( alphasync.stjude.org ), a pipeline and database that provides updated AlphaFold structure models for currently 39,961 UniProt proteins, including isoforms. Moreover, AlphaSync enhances 2.6 million structures with residue-level features, including solvent accessibility, dihedral angles, intrinsic disorder predictions, and 4.7 billion atom-level noncovalent contacts. AlphaSync’s user-friendly interface enables structural analyses at scale across up-to-date proteomes for 42 species.
Year:
2025
T cell receptor (TCR) engagement initiates the activation process, and this signaling event is regulated in multifaceted ways. Nutrient availability in the immediate niche is one such mode of regulation. Here, we investigated how the availability of an essential amino acid methionine (Met) and TCR signaling might interplay in the earliest events of T cell activation to affect subsequent T cell fate and function. We found that limiting Met during only the initial 30 minutes of CD8+ T cell activation increased Ca2+ influx, Ca2+-mediated NFAT1 (Nfatc2) activation, NFAT1 promoter occupancy, and T cell exhaustion. We identified changes in the protein arginine methylome during the initial 30 min of TCR engagement and discovered a novel arginine methylation of a Ca2+-activated potassium transporter, KCa3.1, which regulates Ca2+-mediated NFAT1 signaling to ensure optimal activation. Ablation of arginine methylation in KCa3.1 led to increased NFAT1 activation, rendering T cells dysfunctional in murine tumour and infection models. Furthermore, acute Met supplementation at early stages reduced nuclear NFAT1 in tumour-infiltrating T cells and augmented their anti-tumour activity. Our findings identify a metabolic event occurring early after T cell activation that influences the subsequent fate of the cell.
Year:
2024
Collaborators (15)
Robert Autry
Group Leader- Clinical Bioinformatics -Translational Genomics
Deutsches Krebsforschungszentrum
Jeremy Jones
Scientist
St. Jude Children's Research Hospital
Giedre Krenciute
Associate Member
St. Jude Children's Research Hospital
Charles Gawad
Stanford University School of Medicine
Gang Wu
Associate Member
St. Jude Children's Research Hospital
Douglas Green
Chair
St. Jude Children's Research Hospital
Jinghui Zhang
Professor
St. Jude Children's Research Hospital
Evan Glazer
Professor
University of Michigan
Catherine E Welsh
Associate Professor
Hope College
Konstantin Andreev
Scientist
St. Jude Children's Research Hospital
Jiyang Yu
Interim Chair
St. Jude Children's Research Hospital
John Christodoulou
University College London
Richard Webby
St. Jude Children's Research Hospital
Junmin Peng
Member (Professor)
St. Jude Children's Research Hospital
Ahmed Kandeil
St. Jude Children's Research Hospital
Make your next move.
Prepare your application
Review drafts before you send them.